Proteomics Shared Resource

蛋白质组学共享资源（PSR） 蛋白质是生物学的最终执行者，几乎所有的细胞过程都依赖于蛋白质。 由基因的蛋白质产物完成的分子工作。此外，还有巨大的监管潜力， 可以通过可逆的化学翻译后调节蛋白质功能， 修饰和与其他蛋白质伴侣的相互作用。由于这些功能，大多数癌症 药物直接作用于蛋白质靶或产生对蛋白质功能的依赖性（例如，DNA损伤剂 压倒参与修复的蛋白酶）。目前，在癌症研究中， 在没有蛋白质网络动力学知识的情况下（即，蛋白质组动力学），基因组和 转录组学数据通常不足以确定可靶向的或“可操作的”事件和机制 对治疗的抵抗。蛋白质组学在癌症研究中的目标是确定复杂和复杂的蛋白质组学的扰动， 与癌症的发展和进展相关的动态蛋白质信号传导网络以及其用途 这些信息用于鉴定新的治疗靶点和生物标志物， 对特定疗法的抵抗。我们已经建立了一个全面的蛋白质生物学共享资源， 在癌症生物学和蛋白质生物化学方面有很强的背景。由于没有单一的技术平台， 分析细胞蛋白质组的各个方面，多重富集，纯化和测量方法 已开发，以解决DLDCCC研究人员研究的各种研究问题。具体来说，我们 共享资源提供基于靶向抗体的蛋白质分析与定制RPPA平台和一套 用于表达谱分析和确定蛋白质相互作用的基于质谱的测定。此外，委员会认为， 认识到“大数据”的挑战，我们努力在数据分析和沟通方面取得卓越成就。我们 因此，提供的服务是全程跟踪包，以协助研究者进行前期研究设计 和可行性评估，通过各种技术平台进行实验分析， 数据分析和解释、故障排除和后续研究中的决策。

PROJECT SUMMARY: Proteomics Shared Resource (PSR) Proteins are the ultimate executors of biology, with nearly all cellular processes being dependent on the molecular work performed by protein products of genes. Furthermore, there is a tremendous regulatory potential that can be acutely utilized through fine-tuning of protein function through reversible chemical post-translational modifications and interactions with other protein partners. Because of these functionalities, a majority of cancer drugs act directly on protein targets or create a dependency on a protein function (e.g., DNA damage agents that overwhelm protein enzymes involved in repair). It is now an increasing realization in the cancer research field that without knowledge of the dynamics of protein networks (i.e., proteome dynamics), genomic and transcriptomic data are often insufficient for determination of targetable, or “actionable,” events and mechanisms of resistance to treatment. The goal of proteomics in cancer research is to define perturbations of complex and dynamic protein signaling networks that are associated with development and progression of cancer and to use this information for identification of novel therapeutic targets and biomarkers that can predict response or resistance to specific therapies. We have established a comprehensive Shared Resource for protein biology with a strong background in cancer biology and protein biochemistry. Since there is no single technology platform to analyze all aspects of the cellular proteome, multiple enrichment, purification, and measurement approaches have been developed to address diverse research questions studied by DLDCCC investigators. Specifically, our Shared Resource provides targeted antibody-based protein profiling with custom RPPA platform and a suite of mass spectrometry-based assays for expression profiling and determination of protein interactions. Furthermore, recognizing the challenges of “big data,” we strive for excellence in data analysis and communication. Our services are therefore provided as beginning-to-end packages to assist investigators with up-front study design and feasibility assessment, execution of experimental analysis by various technology platforms, specialized analysis and interpretation of data, troubleshooting, and decision-making in follow-up studies.